Search

Your search keyword '"Scher, Jose U."' showing total 49 results
Start Over Author "Scher, Jose U." Publication Year Range Last 3 years
49 results on '"Scher, Jose U."'

3. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry

Author

Jin, Joy Q., Cronin, Angel, Roberts-Toler, Carla, Yeroushalmi, Samuel, Hadeler, Edward, Spencer, Riley K., Elhage, Kareem G., Gondo, George, Wallace, Elizabeth B., Reddy, Soumya M., Han, George, Kaffenberger, Jessica, Davis, Mitchell S., Hakimi, Marwa, Scher, Jose U., Armstrong, April W., Bhutani, Tina, McLean, Robert R., and Liao, Wilson

Published
2023
Full Text
View/download PDF

5. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

Author

Ogdie, Alexis, primary, Merola, Joseph F., additional, Mease, Philip J., additional, Ritchlin, Christopher T., additional, Scher, Jose U., additional, Lafferty, Kimberly Parnell, additional, Chan, Daphne, additional, Chakravarty, Soumya D., additional, Langholff, Wayne, additional, Wang, Yanli, additional, Choi, Olivia, additional, Krol, Yevgeniy, additional, and Gottlieb, Alice B., additional

Published
2024
Full Text
View/download PDF

7. Racial and ethnic determinants of psoriatic arthritis phenotypes and disease activity

Author

Haberman, Rebecca H, primary, Ahmed, Tasneem, additional, Um, Seungha, additional, Zhou, Ying Yin, additional, Catron, Sydney, additional, Jano, Kathryn, additional, Felipe, Adamary, additional, Eichman, Stephanie, additional, Rice, Alexandra L, additional, Lydon, Eileen, additional, Moussavi, Sarah, additional, Neimann, Andrea L, additional, Reddy, Soumya M, additional, Adhikari, Samrachana, additional, and Scher, Jose U, additional

Published
2024
Full Text
View/download PDF

8. Clinical validation of digital assessment tools and machine learning models for remote measurement of psoriasis and psoriatic arthritis: a proof-of-concept study

Author

Webster, Dan, Haberman, Rebecca H., Chada, Lourdes Maria Perez, Tummalacherla, Meghasyam, Tediarjo, Aryton, Yadav, Vijay, Neto, Elias Chaibub, MacDuffie, Woody, DePhillips, Michael, Sieg, Eric, Catron, Sydney, Grant, Carly, Francis, Wynona, Nguyen, Marina, Yussuff, Muibat, Castillo, Rochelle, Yan, Di, Neimann, Andrea L., Reddy, Soumya M., Ogdie, Alexis, Kolivras, Athanassios, Kellen, Michael, Mangravite, Lara, Sieberts, Solveig, Omberg, Larsson, Merola, Joseph, Scher, Jose U., Webster, Dan, Haberman, Rebecca H., Chada, Lourdes Maria Perez, Tummalacherla, Meghasyam, Tediarjo, Aryton, Yadav, Vijay, Neto, Elias Chaibub, MacDuffie, Woody, DePhillips, Michael, Sieg, Eric, Catron, Sydney, Grant, Carly, Francis, Wynona, Nguyen, Marina, Yussuff, Muibat, Castillo, Rochelle, Yan, Di, Neimann, Andrea L., Reddy, Soumya M., Ogdie, Alexis, Kolivras, Athanassios, Kellen, Michael, Mangravite, Lara, Sieberts, Solveig, Omberg, Larsson, Merola, Joseph, and Scher, Jose U.

Abstract

Objective Psoricatic disease remains underdiagnosed and undertreated. We developed and validated a suite of novel, smartphone sensor-based assessments that can be self-administered to measure cutaneous and musculoskeletal signs and symptoms of psoriatic disease. Methods Participants with psoriasis, psoriatic arthritis, or healthy controls were recruited between June 5, 2019, and November 10, 2021, at two academic medical centers. Concordance and accuracy of digital measures and image-based machine learning models were compared to their analogous clinical measures from trained rheumatologists and dermatologists. Results Of 104 study participants, 51 (49%) were female and 53 (51%) were male, with a mean age of 42.3 years (SD: 12.6). Seventy-nine (76%) participants had psoriatic arthritis, 16 (15.4%) had psoriasis and 9 (8.7%) were healthy controls. Digital patient assessment of percent body surface area (BSA) affected with psoriasis demonstrated very strong concordance (CCC = 0.94, [95%CI = 0.91–0.96]) with physician-assessed BSA. The in-clinic and remote target-lesion Physician Global Assessments showed fair to moderate concordance (CCC erythema =0.72 [0.59–0.85]; CCC induration =0.72 [0.62–0.82]; CCC scaling =0.60 [0.48–0.72]). Machine learning models of hand photos taken by patients accurately identified clinically-diagnosed nail psoriasis with an accuracy of 0.76. The Digital Jar Open assessment categorized physician-assessed upper extremity involvement, considering joint tenderness or enthesitis (AUROC = 0.68 (0.47–0.85)). Conclusion The Psorcast digital assessments achieved significant clinical validity, although they require further validation in larger cohorts before use in evidence-based medicine or clinical trial settings. The smartphone software and analysis pipelines from the Psorcast suite are open source and freely available., info:eu-repo/semantics/published

Published
2024

11. Psoriatic arthritis

Author

FitzGerald, Oliver, Ogdie, Alexis, Chandran, Vinod, Coates, Laura C., Kavanaugh, Arthur, Tillett, William, Leung, Ying Ying, deWit, Maarten, Scher, Jose U., and Mease, Philip J.

Published
2021
Full Text
View/download PDF

12. Mitigation of Osteoclast‐Mediated Arthritic Bone Remodeling By Short Chain Fatty Acids.

Author

Yang, Katharine Lu, Mullins, Briana J., Lejeune, Alannah, Ivanova, Ellie, Shin, Jong, Bajwa, Sofia, Possemato, Richard, Cadwell, Ken, Scher, Jose U., and Koralov, Sergei B.

Subjects
OSTEOPOROSIS prevention, FLOW cytometry, SHORT-chain fatty acids, DATA analysis, POLYMERASE chain reaction, COMPUTED tomography, ENZYME-linked immunosorbent assay, MANN Whitney U Test, DESCRIPTIVE statistics, MICE, GAS chromatography, RNA, OSTEOCLASTS, ARTHRITIS, ANIMAL experimentation, MASS spectrometry, STATISTICS, HEMATOPOIETIC stem cells, STEM cells, DATA analysis software, BONE remodeling, PHENOTYPES, GENOTYPES, SEQUENCE analysis, NONPARAMETRIC statistics
Abstract

Objective: The objective for this study was to evaluate the effects of short chain fatty acids (SCFAs) on arthritic bone remodeling. Methods: We treated a recently described preclinical murine model of psoriatic arthritis (PsA), R26STAT3Cstopfl/fl CD4Cre mice, with SCFA‐supplemented water. We also performed in vitro osteoclast differentiation assays in the presence of serum‐level SCFAs to evaluate the direct impact of these microbial metabolites on maturation and function of osteoclasts. We further characterized the molecular mechanism of SCFAs by transcriptional analysis. Results: The osteoporosis condition in R26STAT3Cstopfl/fl CD4Cre animals is attributed primarily to robust osteoclast differentiation driven by an expansion of osteoclast progenitor cells (OCPs), accompanied by impaired osteoblast development. We show that SCFA supplementation can rescue the osteoporosis phenotype in this model of PsA. Our in vitro experiments revealed an inhibitory effect of the SCFAs on osteoclast differentiation, even at very low serum concentrations. This suppression of osteoclast differentiation enabled SCFAs to impede osteoporosis development in R26STAT3Cstopfl/fl CD4Cre mice. Further interrogation revealed that bone marrow–derived OCPs from diseased mice expressed a higher level of SCFA receptors than those of control mice and that the progenitor cells in the bone marrow of SCFA‐treated mice presented a modified transcriptomic landscape, suggesting a direct impact of SCFAs on bone marrow progenitors in the context of osteoporosis. Conclusion: We demonstrated how gut microbiota‐derived SCFAs can regulate distal pathology (ie, osteoporosis) and identified a potential therapeutic option for restoring bone density in rheumatic disease, further highlighting the critical role of the gut–bone axis in these disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings

Author

Grant, Carly, primary, Perez-Chada, Lourdes, additional, Haberman, Rebecca H., additional, Webster, Daniel, additional, FitzGerald, Oliver, additional, Ritchlin, Christopher, additional, Chandran, Vinod, additional, Rosen, Cheryl F., additional, Weber, Brittany, additional, Garshick, Michael, additional, Eder, Lihi, additional, Reddy, Soumya M., additional, Ogdie, Alexis, additional, Scher, Jose U., additional, and Merola, Joseph F., additional

Published
2023
Full Text
View/download PDF

15. Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems

Author

Castillo, Rochelle L., primary, Sidhu, Ikjot, additional, Dolgalev, Igor, additional, Chu, Tinyi, additional, Prystupa, Aleksandr, additional, Subudhi, Ipsita, additional, Yan, Di, additional, Konieczny, Piotr, additional, Hsieh, Brandon, additional, Haberman, Rebecca H., additional, Selvaraj, Shanmugapriya, additional, Shiomi, Tomoe, additional, Medina, Rhina, additional, Girija, Parvathy Vasudevanpillai, additional, Heguy, Adriana, additional, Loomis, Cynthia A., additional, Chiriboga, Luis, additional, Ritchlin, Christopher, additional, Garcia-Hernandez, Maria De La Luz, additional, Carucci, John, additional, Meehan, Shane A., additional, Neimann, Andrea L., additional, Gudjonsson, Johann E., additional, Scher, Jose U., additional, and Naik, Shruti, additional

Published
2023
Full Text
View/download PDF

18. Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study

Author

Webster, Dan E., Haberman, Rebecca H., Perez-Chada, Lourdes M., Tummalacherla, Meghasyam, Tediarjo, Aryton, Yadav, Vijay, Neto, Elias Chaibub, MacDuffie, Woody, DePhillips, Michael, Sieg, Eric, Catron, Sydney, Grant, Carly, Francis, Wynona, Nguyen, Marina, Yussuff, Muibat, Castillo, Rochelle L., Yan, Di, Neimann, Andrea L., Reddy, Soumya M., Ogdie, Alexis, Kolivras, Athanassios, Kellen, Michael R., Mangravite, Lara M., Sieberts, Solveig K., Omberg, Larsson, Merola, Joseph F., and Scher, Jose U.

Abstract

ObjectivePsoriatic disease remains underdiagnosed and undertreated. We developed and validated a suite of novel, sensor-based smartphone assessments (Psorcast app) that can be self-administered to measure cutaneous and musculoskeletal signs and symptoms of psoriatic disease.MethodsParticipants with psoriasis (PsO) or psoriatic arthritis (PsA) and healthy controls were recruited between June 5, 2019, and November 10, 2021, at 2 academic medical centers. Concordance and accuracy of digital measures and image-based machine learning models were compared to their analogous clinical measures from trained rheumatologists and dermatologists.ResultsOf 104 study participants, 51 (49%) were female and 53 (51%) were male, with a mean age of 42.3 years (SD 12.6). Seventy-nine (76%) participants had PsA, 16 (15.4%) had PsO, and 9 (8.7%) were healthy controls. Digital patient assessment of percent body surface area (BSA) affected with PsO demonstrated very strong concordance (Lin concordance correlation coefficient [CCC] 0.94 [95% CI 0.91-0.96]) with physician-assessed BSA. The in-clinic and remote target plaque physician global assessments showed fair-to-moderate concordance (CCCerythema0.72 [0.59-0.85]; CCCinduration0.72 [0.62-0.82]; CCCscaling0.60 [0.48-0.72]). Machine learning models of hand photos taken by patients accurately identified clinically diagnosed nail PsO with an accuracy of 0.76. The Digital Jar Open assessment categorized physician-assessed upper extremity involvement, considering joint tenderness or enthesitis (AUROC 0.68 [0.47-0.85]).ConclusionThe Psorcast digital assessments achieved significant clinical validity, although they require further validation in larger cohorts before use in evidence-based medicine or clinical trial settings. The smartphone software and analysis pipelines from the Psorcast suite are open source and freely available.

Published
2024
Full Text
View/download PDF

20. Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin

Author

Boix-Amorós, Alba, primary, Badri, Michelle H, additional, Manasson, Julia, additional, Blank, Rebecca B, additional, Haberman, Rebecca H, additional, Neimann, Andrea L, additional, Girija, Parvathy V, additional, Jimenez Hernandez, Anthony, additional, Heguy, Adriana, additional, Koralov, Sergei B, additional, Bonneau, Richard, additional, Clemente, Jose C, additional, and Scher, Jose U, additional

Published
2022
Full Text
View/download PDF

21. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

Author

Haberman, Rebecca H, primary, MacFarlane, Katrina A, additional, Catron, Sydney, additional, Samuels, Jonathan, additional, Blank, Rebecca B, additional, Toprover, Michael, additional, Uddin, Zakwan, additional, Hu, Jiyuan, additional, Castillo, Rochelle, additional, Gong, Cinty, additional, Qian, Kun, additional, Piguet, Vincent, additional, Tausk, Francisco, additional, Yeung, Jensen, additional, Neimann, Andrea L, additional, Gulliver, Wayne, additional, Thiele, Ralf G, additional, Merola, Joseph F, additional, Ogdie, Alexis, additional, Rahman, Proton, additional, Chakravarty, Soumya D, additional, Eder, Lihi, additional, Ritchlin, C T, additional, and Scher, Jose U, additional

Published
2022
Full Text
View/download PDF

22. Supplemental Material - Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

Author

Haberman, Rebecca H., Um, Seungha, Catron, Sydney, Chen, Alan, Lydon, Eileen, Attur, Malavikalakshmi, Neimann, Andrea L., Reddy, Soumya, Troxel, Andrea, Adhikari, Samrachana, and Scher, Jose U.

Subjects
Medicine
Abstract

Supplemental Material for Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center by Rebecca H. Haberman, MD, Seungha Um, PhD, Sydney Catron, BS, Alan Chen, BA, Eileen Lydon, NP, Malavikalakshmi Attur, MD, Andrea L. Neimann, MD, Soumya Reddy, MD, Andrea Troxel, ScD, Samrachana Adhikari, PhD and Jose U. Scher, MD in Journal of Psoriasis and Psoriatic Arthritis®

Published
2023
Full Text
View/download PDF

24. Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City

Author

Saxena, Amit, primary, Engel, Alexis J, additional, Banbury, Brittany, additional, Hasan, Ghadeer, additional, Fraser, Nicola, additional, Zaminski, Devyn, additional, Masson, Mala, additional, Haberman, Rebecca H, additional, Scher, Jose U, additional, Ho, Gary, additional, Law, Jammie, additional, Rackoff, Paula, additional, Tseng, Chung-E, additional, Belmont, H Michael, additional, Clancy, Robert M, additional, Buyon, Jill P, additional, and Izmirly, Peter M, additional

Published
2022
Full Text
View/download PDF

25. COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study

Author

Yan, Di, primary, Kolla, Avani M., additional, Young, Trevor, additional, Fried, Lauren, additional, Shankar, Shruthi, additional, Rangel, Lauren, additional, Yin, Lu, additional, Castillo, Rochelle, additional, Steuer, Alexa, additional, Svigos, Katerina, additional, Izmirly, Peter, additional, Sekar, Vaish, additional, Lesser, Robert, additional, Solomon, Gary, additional, Blank, Rebecca B., additional, Haberman, Rebecca H., additional, Neimann, Andrea L., additional, and Scher, Jose U., additional

Published
2022
Full Text
View/download PDF

28. Responsiveness and Minimum Clinically Important Difference in Patient‐ReportedOutcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study

Author

Karmacharya, Paras, Stull, Courtney, Stephens‐Shields, Alisa, Husni, M. Elaine, Scher, Jose U., Craig, Ethan, Fitzsimmons, Robert, Reddy, Soumya M., Magrey, Marina N., Ogdie, Alexis, and Walsh, Jessica A.

Abstract

To determine the responsiveness to therapy and minimum clinically important improvement (MCII) for patient‐reported outcome measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demonstrate change. A longitudinal cohort study was performed within the PsA Research Consortium. Patients completed several patient‐reported outcomes, including the Routine Assessment of Patient Index Data, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Psoriatic Arthritis Impact of Disease 12‐item (PsAID12) questionnaire, and others. The mean change in the scores between visits and standardized response means (SRMs) were calculated. The MCII was calculated as the mean change in score among patients who reported minimal improvement. SRMs and MCIIs were compared among subgroups with moderate to highly active PsA and those with lower disease activity. Among 171 patients, 266 therapy courses were included. The mean ± SD age was 51 ± 13.8 years, 53% were female, and the mean swollen and tender joint counts were 3 and 6, respectively, at baseline. SRMs and MCII for all measures were small to moderate, although greater among those with higher baseline disease activity. BASDAI had the best SRM overall and for less active PsA, and the clinical Disease Activity of PsA (cDAPSA) and PsAID12 were best for those with higher disease activity. SRMs and MCII were relatively small in this real‐world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA, and PsAID12 had good sensitivity to change, but selection for use in trials should consider the baseline disease activity of patients to be enrolled.

Published
2023
Full Text
View/download PDF

29. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease

Author

Haberman, Rebecca H, primary, Um, Seungha, additional, Axelrad, Jordan E, additional, Blank, Rebecca B, additional, Uddin, Zakwan, additional, Catron, Sydney, additional, Neimann, Andrea L, additional, Mulligan, Mark J, additional, Herat, Ramin Sedaghat, additional, Hong, Simon J, additional, Chang, Shannon, additional, Myrtaj, Arnold, additional, Ghiasian, Ghoncheh, additional, Izmirly, Peter M, additional, Saxena, Amit, additional, Solomon, Gary, additional, Azar, Natalie, additional, Samuels, Jonathan, additional, Golden, Brian D, additional, Rackoff, Paula, additional, Adhikari, Samrachana, additional, Hudesman, David P, additional, and Scher, Jose U, additional

Published
2022
Full Text
View/download PDF

30. A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation

Author

Garshick, Michael S., primary, Drenkova, Kamelia, additional, Barrett, Tessa J., additional, Schlamp, Florencia, additional, Fisher, Edward A., additional, Katz, Stuart, additional, Jelic, Sanja, additional, Neimann, Andrea L., additional, Scher, Jose U., additional, Krueger, James, additional, and Berger, Jeffrey S., additional

Published
2022
Full Text
View/download PDF

31. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis

Author

Blank, Rebecca B, primary, Haberman, Rebecca H, additional, Qian, Kun, additional, Samanovic, Marie, additional, Castillo, Rochelle, additional, Jimenez Hernandez, Anthony, additional, Vasudevapillai Girija, Parvathy, additional, Catron, Sydney, additional, Uddin, Zakwan, additional, Rackoff, Paula, additional, Solomon, Gary, additional, Azar, Natalie, additional, Rosenthal, Pamela, additional, Izmirly, Peter, additional, Samuels, Jonathan, additional, Golden, Brian, additional, Reddy, Soumya, additional, Mulligan, Mark J, additional, Hu, Jiyuan, additional, and Scher, Jose U, additional

Published
2022
Full Text
View/download PDF

33. Clinical validation of digital biomarkers and machine learning models for remote measurement of psoriasis and psoriatic arthritis

Author

Webster, Dan E., primary, Haberman, Rebecca H., additional, Perez Chada, Lourdes Maria, additional, Tummalacherla, Meghasyam, additional, Tediarjo, Aryton, additional, Yadav, Vijay, additional, Neto, Elias Chaibub, additional, MacDuffie, Woody, additional, DePhillips, Michael, additional, Sieg, Eric, additional, Catron, Sydney, additional, Grant, Carly, additional, Francis, Wynona, additional, Nguyen, Marina, additional, Yussuff, Muibat, additional, Castillo, Rochelle L., additional, Yan, Di, additional, Neimann, Andrea L., additional, Reddy, Soumya M., additional, Ogdie, Alexis, additional, Kolivras, Athanassios, additional, Kellen, Michael R., additional, Mangravite, Lara M., additional, Sieberts, Solveig K., additional, Omberg, Larsson, additional, Merola, Joseph F., additional, and Scher, Jose U., additional

Published
2022
Full Text
View/download PDF

34. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

Author

Nguyen, Tien, primary, Churchill, Melvin, additional, Levin, Robert, additional, Valenzuela, Guillermo, additional, Merola, Joseph F., additional, Ogdie, Alexis, additional, Orbai, Ana-Maria, additional, Scher, Jose U., additional, Kavanaugh, Arthur, additional, Kianifard, Farid, additional, Rollins, Chauncy, additional, Calheiros, Renato, additional, and Chambenoit, Olivier, additional

Published
2022
Full Text
View/download PDF

35. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting

Author

Stober, Carmel, primary, McInnes, Iain B., additional, Raychaudhuri, Soumya, additional, Mease, Philip J., additional, Pennington, Stephen R., additional, Scher, Jose U., additional, Chandran, Vinod, additional, Armstrong, April W., additional, de Wit, Maarten, additional, Cauli, Alberto, additional, Jadon, Deepak R., additional, Löve, Thorvardur J., additional, Ogdie, Alexis, additional, O'Sullivan, Denis, additional, van Mens, Leonieke J.J., additional, Ritchlin, Christopher T., additional, and FitzGerald, Oliver, additional

Published
2022
Full Text
View/download PDF

36. GRAPPA 2020 Research Award Recipients

Author

Castillo, Rochelle L., primary, Yan, Di, additional, Ashhurst, Anneliese S., additional, Elliott, Ashley, additional, Angioni, Maria Maddalena, additional, Scher, Jose U., additional, Naik, Shruti, additional, Neimann, Andrea, additional, Byrne, Scott N., additional, Payne, Richard J., additional, FitzGerald, Oliver, additional, Pennington, Stephen R., additional, Cauli, Alberto, additional, and Chandran, Vinod, additional

Published
2022
Full Text
View/download PDF

40. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS – CoV ‐2 Vaccination

Author

Izmirly, Peter M., primary, Kim, Mimi Y., additional, Samanovic, Marie, additional, Fernandez‐Ruiz, Ruth, additional, Ohana, Sharon, additional, Deonaraine, Kristina K., additional, Engel, Alexis J., additional, Masson, Mala, additional, Xie, Xianhong, additional, Cornelius, Amber R., additional, Herati, Ramin S., additional, Haberman, Rebecca H., additional, Scher, Jose U., additional, Guttmann, Allison, additional, Blank, Rebecca B., additional, Plotz, Benjamin, additional, Haj‐Ali, Mayce, additional, Banbury, Brittany, additional, Stream, Sara, additional, Hasan, Ghadeer, additional, Ho, Gary, additional, Rackoff, Paula, additional, Blazer, Ashira D., additional, Tseng, Chung‐E, additional, Belmont, H. Michael, additional, Saxena, Amit, additional, Mulligan, Mark J., additional, Clancy, Robert M., additional, and Buyon, Jill P., additional

Published
2021
Full Text
View/download PDF

41. 1206 Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus

Author

Saxena, Amit, primary, Guttmann, Allison, additional, Masson, Mala, additional, Kim, Mimi Y, additional, Haberman, Rebecca H, additional, Castillo, Rochelle, additional, Scher, Jose U, additional, Deonaraine, Kristina K, additional, Engel, Alexis J, additional, Michael Belmont, H, additional, Blazer, Ashira D, additional, Buyon, Jill P, additional, Fernandez-Ruiz, Ruth, additional, and Izmirly, Peter M, additional

Published
2021
Full Text
View/download PDF

42. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis.

Author

Blank, Rebecca B, Haberman, Rebecca H, Qian, Kun, Samanovic, Marie, Castillo, Rochelle, Hernandez, Anthony Jimenez, Girija, Parvathy Vasudevapillai, Catron, Sydney, Uddin, Zakwan, Rackoff, Paula, Solomon, Gary, Azar, Natalie, Rosenthal, Pamela, Izmirly, Peter, Samuels, Jonathan, Golden, Brian, Reddy, Soumya, Mulligan, Mark J, Hu, Jiyuan, and Scher, Jose U

Subjects
AUTOANTIBODIES, IMMUNIZATION, COVID-19 vaccines, SERUM, SEROCONVERSION, DISEASE incidence, COMPARATIVE studies, TREATMENT effectiveness, MESSENGER RNA, RHEUMATOID arthritis, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics, LONGITUDINAL method, PHARMACODYNAMICS
Abstract

Objectives Autoantibody seroconversion has been extensively studied in the context of COVID-19 infection but data regarding post-vaccination autoantibody production is lacking. Here we aimed to determine the incidence of common autoantibody formation following mRNA COVID-19 vaccines in patients with inflammatory arthritis (IA) and in healthy controls. Methods Autoantibody seroconversion was measured by serum ELISA in a longitudinal cohort of IA participants and healthy controls before and after COVID-19 mRNA-based immunization. Results Overall, there was a significantly lower incidence of ANA seroconversion in participants who did not contract COVID-19 prior to vaccination compared with those who been previously infected (7.4% vs 24.1%, P  = 0.014). Incidence of de novo anti-CCP seroconversion in all participants was low at 4.9%. Autoantibody levels were typically of low titre, transient, and not associated with increase in IA flares. Conclusions In both health and inflammatory arthritis, the risk of autoantibody seroconversion is lower following mRNA-based immunization than following natural SARS-CoV-2 infection. Importantly, seroconversion does not correlate with self-reported IA disease flare risk, further supporting the encouragement of mRNA-based COVID-19 immunization in the IA population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures

Author

Herrera, Alberto, primary, Cheng, Anthony, additional, Mimitou, Eleni P., additional, Seffens, Angelina, additional, George, Dean, additional, Bar-Natan, Michal, additional, Heguy, Adriana, additional, Ruggles, Kelly V., additional, Scher, Jose U., additional, Hymes, Kenneth, additional, Latkowski, Jo-Ann, additional, Ødum, Niels, additional, Kadin, Marshall E., additional, Ouyang, Zhengqing, additional, Geskin, Larisa J., additional, Smibert, Peter, additional, Buus, Terkild B., additional, and Koralov, Sergei B., additional

Published
2021
Full Text
View/download PDF

44. Does biologic therapy impact the development of PsA among patients with psoriasis?

Author

Meer, Elana, primary, Merola, Joseph F, additional, Fitzsimmons, Robert, additional, Love, Thorvardur Jon, additional, Wang, Shiyu, additional, Shin, Daniel, additional, Chen, Yong, additional, Xie, Sharon, additional, Choi, Hyon, additional, Zhang, Yuqing, additional, Scher, Jose U, additional, Ritchlin, C T, additional, Gelfand, Joel M, additional, and Ogdie, Alexis, additional

Published
2021
Full Text
View/download PDF

45. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination.

Author

Izmirly, Peter M., Kim, Mimi Y., Samanovic, Marie, Fernandez‐Ruiz, Ruth, Ohana, Sharon, Deonaraine, Kristina K., Engel, Alexis J., Masson, Mala, Xie, Xianhong, Cornelius, Amber R., Herati, Ramin S., Haberman, Rebecca H., Scher, Jose U., Guttmann, Allison, Blank, Rebecca B., Plotz, Benjamin, Haj‐Ali, Mayce, Banbury, Brittany, Stream, Sara, and Hasan, Ghadeer

Subjects
AUTOANTIBODIES, IMMUNIZATION, IMMUNOGLOBULINS, B cells, PREDNISOLONE, COVID-19 vaccines, SEVERITY of illness index, INTERFERONS, IMMUNITY, QUESTIONNAIRES, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics, SYSTEMIC lupus erythematosus, T cells, LOGISTIC regression analysis, IMMUNOSUPPRESSIVE agents
Abstract

Objective: To evaluate seroreactivity and disease flares after COVID‐19 vaccination in a multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE). Methods: Ninety SLE patients and 20 healthy controls receiving a complete COVID‐19 vaccine regimen were included. IgG seroreactivity to the SARS–CoV‐2 spike receptor‐binding domain (RBD) and SARS–CoV‐2 microneutralization were used to evaluate B cell responses; interferon‐γ (IFNγ) production was measured by enzyme‐linked immunospot (ELISpot) assay in order to assess T cell responses. Disease activity was measured by the hybrid SLE Disease Activity Index (SLEDAI), and flares were identified according to the Safety of Estrogens in Lupus Erythematosus National Assessment–SLEDAI flare index. Results: Overall, fully vaccinated SLE patients produced significantly lower IgG antibodies against SARS–CoV‐2 spike RBD compared to fully vaccinated controls. Twenty‐six SLE patients (28.8%) generated an IgG response below that of the lowest control (<100 units/ml). In logistic regression analyses, the use of any immunosuppressant or prednisone and a normal anti–double‐stranded DNA antibody level prior to vaccination were associated with decreased vaccine responses. IgG seroreactivity to the SARS–CoV‐2 spike RBD strongly correlated with the SARS–CoV‐2 microneutralization titers and correlated with antigen‐specific IFNγ production determined by ELISpot. In a subset of patients with poor antibody responses, IFNγ production was similarly diminished. Pre‐ and postvaccination SLEDAI scores were similar in both groups. Postvaccination flares occurred in 11.4% of patients; 1.3% of these were severe. Conclusion: In a multiethnic/multiracial study of SLE patients, 29% had a low response to the COVID‐19 vaccine which was associated with receiving immunosuppressive therapy. Reassuringly, severe disease flares were rare. While minimal protective levels remain unknown, these data suggest that protocol development is needed to assess the efficacy of booster vaccination. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Contributors

Author

Abelson, Abby G., Abraham, Mary, Abramson, Steven B., Adachi, Jonathan D., Aggarwal, Rohit, Akira, Shizuo, Aletaha, Daniel, Ashraf Ali, Amjid, Allem, Kavitta B., Almehthel, Mohammed, Almohaya, Mohammed, Riera Alonso, Elena, Amigo, Mary-Carmen, Aringer, Martin, Arkema, Elizabeth V., Ascherman, Dana P., Atamas, Sergei P., Atkinson, Timothy J., Azeez, Maha A., Baer, Alan N., Baraliakos, Xenofon, Bardin, Thomas, Barnsley, Leslie, Barr, Andrew J., Bathon, Joan M., Belch, Jill J.F., Bellido, Teresita, Ben-Artzi, Ami, Benedetti, Fabrizio, Bennell, Kim L., Bennett, Sarah E., Berard, Roberta A., Berenbaum, Francis, Berman, Brian, Bermas, Bonnie L., Elizabeth Berry, Alice, Bertsias, George, Bhana, Suleman, Bhattacharyya, Shamik, Bilginer, Yelda, Bleasel, Jane F., Block, Joel A., Böhm, Markus, Bonelli, Michael, Boumpas, Dimitrios T., Bozec, Aline, Brasington, Richard D., Braun, Jürgen, Brouwer, Elisabeth, Brown, Jacques P., Brown, Matthew A., Brown, Matthew L., Buch, Maya H., Buckley, Christopher D., Bugbee, William D., Burmester, Gerd-Rüdiger, Burns, Jane C., Burr, David B., Buttgereit, Frank, Buxbaum, Joel N., Bykerk, Vivian P., Calabrese, Cassandra, Calabrese, Leonard H., Callen, Jeffrey P., Carr, Andrew J., Carrino, John A., Cavallo, Sabrina, Cervera, Ricard, Chang, Christopher, Chang, Joyce C., Chaon, Benjamin C., Chaudhary, Prateek, Choi, Hyon K., Choy, Ernest H.S., Christopher-Stine, Lisa, Chung, Lorinda, Ciccia, Francesco, Clauw, Daniel J., Clinch, Jacqui, Clowse, Megan E.B., Coghlan, John (Gerry), Colbert, Robert A., Conaghan, Philip G., Cooper, Cyrus, Costello, Wendy, Costenbader, Karen H., Cox, George L.D., Creamer, Paul, Cronstein, Bruce N., Cross, Raymond K., Curtis, Jeffrey R., D'Adamo, Chris, D'Agati, Vivette D., Daikh, David I., Dakin, Stephanie G., Dalbeth, Nicola, Davis, Aileen M., D'Cruz, David P., Eduardo de Barros Branco, Carlos, de Boer, Berber, De Craemer, Ann-Sophie, de Jesus, Adriana A., De Vita, Salvatore, de Wit, Maarten, Deal, Chad L., Deane, Kevin D., Dellaripa, Paul F., Dennison, Elaine, Denton, Christopher P., DiCarlo, Edward F., Distler, Oliver, Donlan, Pamela, Doyle, Tracy J., du Preez, Hannah, Dyer, George S.M., Eastell, Richard, Ehrchen, Jan, Elewaut, Dirk, Emery, Paul, Emmerling, Max R., Espinosa, Gerard, Espinoza, Luis R., Eyre, Stephen, Fanouriakis, Antonis, Farber, Joshua, Fasth, Anders, Feist, Eugen, Feldman, Candace H., Fernandez-Ruiz, Ruth, Filer, Andrew, Fiorentino, David F., Fisher, Benjamin A., Fisk, John D., Flajnik, Martin F., Forbess, Lindsy, Fox, David A., Frech, Tracy M., Frisaldi, Elisa, Gabay, Cem, Gadina, Massimo, Gandolfo, Saviana, Garelick, Daniela, Gay, Steffen, Geifman, Nophar, George, Michael D., Eric Gershwin, M., Ghadiali, Jay, Gilis, Elisabeth, Gold, Deborah T., Gold, Garry E., Goldbach-Mansky, Raphaela, Gómez-Puerta, José A., Goodman, Susan M., Gordon, Caroline, Gordon, Sharon, Gossec, Laure, Grainger, Andrew J., Grainger, Rebecca, Gravallese, Ellen M., Greenberg, Jeffrey D., Guglielmi, Luiza Guilherme, Gül, Ahmet, Gullapalli, Rao P., Guma, Monica, Gupta, Sarthak, Han, Shuhong, Hanly, John G., Hanson, Eric P., Haraoui, Boulos, Harley, John B., Haroun, Tayseer G., Hashkes, Philip J., Hasni, Sarfaraz A., Bassim Hassan, Andrew, Haupt, Lukas, Hausmann, Jonathan S., Hawker, Gillian A., Heiberg, Turid, Helfgott, Simon M., Hinman, Rana S., Hoffmann-Vold, Anna-Maria, Holroyd, Christopher R., Holt, Cathy, Horomanski, Audra, Huizinga, Thomas W.J., Humby, Frances, Elaine Husni, M., Hwang, Jonathan, Hyrich, Kimme, Inman, Robert D., Inoue, Dai, Isaac, Zacharia, Isaacs, John D., Isenberg, David, Iversen, Maura D., Jabs, Douglas A., James, Judith A., Jandali, Bochra, Kassim Javaid, M., Javier, Rose-Marie, Jefferis, Roy, Jeffries, Matlock A., Johnson, Sindhu R., Johnstone, Brian, Helena Jonsson, Anna, Joyce, Andrew A., Jung, Michelle, Kado, Ruba, Kaisho, Tsuneyasu, Kamal, Natasha, Kane, David, Kaplan, Mariana J., Karr, Timothy L., Kassimos, Dimitrios G., Kastner, Daniel L., Katz, Jeffrey N., Kawano, Mitsuhiro, Kay, Jonathan, Keating, Richard M., Kelly, Jennifer A., Kendler, David, Keyser, Randall E., Khamashta, Munther A., Khanna, Dinesh, Khokhar, Kiran, Kiefer, David, King, Lauren K., Kloppenburg, Margreet, Kolasinski, Sharon L., Kolstad, Kathleen D., Kottyan, Leah C., Byers Kraus, Virginia, Kronberger, Leo R.W., Kroopnick, Jeffrey M., Kvien, Tore K., LaBaer, Joshua, Lafyatis, Robert, Lakkis, Jay I., Landewé, Robert B.M., Langford, Carol A., Laster, Marciana L., Latourte, Augustin, Lau, Arthur N., Laurynenka, Viktoryia, Lavin, Robert A., Laxer, Ronald M., Li, Suzanne C., Liao, Katherine P., Lieberman, Scott M., Liew, Jean W., Littlejohn, Geoffrey O., Liu, Eva S., Lo, Lawrence, Lories, Rik J., Luger, Thomas A., Lundberg, Ingrid E., Luqmani, Raashid A., Machado, Pedro M., Machold, Klaus P., Ronald MacKenzie, C., Major, Tanya J., Malfait, Anne-Marie, Malley, Tamir, Manasson, Julia, March, Lyn M., Olivé Marqués, Alejandro, Márquez, Javier, Martin, Paul, Martínez-Lavín, Manuel, Matteson, Eric L., Mayes, Maureen D., McAlindon, Timothy, McCarthy, Edward F., McCarthy, Geraldine M., McDermott, Michael F., McDonnell, Patrick J., McGonagle, Dennis, Simon Meara, Alexa, Mehta, Jay J., Melville, Andrew R., Merola, Joseph F., Micheletti, Robert G., Michou, Laëtitia, Middleton, Rob, Midha, Disha, Mikdashi, Jamal A., Miller, Frederick W., Minden, Kirsten, Miner, Jonathan J., Minhas, Deeba, Helene Moe, Rikke, Möller, Ingrid, Mopuru, Renuka, Mortaji, Parisa, Mueller, Alisa A., Myasoedova, Elena, Namur, Gauthier, Naredo, Esperanza, Navarro-Compán, Victoria, Neerinckx, Barbara, Nelson, Amanda E., Nerviani, Alessandra, Nicolson, Philippa J.A., Nordal, Ellen B., Nöth, Ulrich, Ntatsaki, Eleana, Obenhuber, Tilman, Oddis, Chester V., Ogdie-Beatty, Alexis R., Omar, Ahmed, Ombrello, Michael J., Omisade, Antonina, Onel, Karen B., Ong, Voon H., Orcel, Philippe, Orozco, Gisela, Orr, Carl, O'Shea, John J., Ospelt, Caroline, Østensen, Monika, Özen, Seza, Park, Elizabeth, Parker, Matthew J.S., Pathan, Ejaz, Patrono, Carlo, Perez-Chada, Lourdes M., Pijnenburg, Luc, Pillinger, Michael H., Pineda, Carlos, Pipitone, Nicolò, Pitzalis, Costantino, Poddubnyy, Denis, Pope, Janet E., Postolova, Anna, Price, Andrew J., Pryor, Katherine P., Quartuccio, Luca, Rackwitz, Lars, Radner, Helga, Rajendran, Aardra, Ramiro, Sofia, Raychaudhuri, Soumya, Redmond, Anthony C., Reeves, Westley H., Remmers, Elaine F., Requena, Luis, Reynolds, Gary, Reynolds, John A., Ribbens, Clio, Richards, Bethan, Richardson, Bruce, Richette, Pascal, Ritchlin, Christopher T., Ritter, Susan Y., Robinson, Philip C., Robinson, William H., Rogers, Valerie J., Romain, Paul L., Rosas, Ivan O., Rosenthal, Ann K., Rubin, Elka, Rudwaleit, Martin, Rutgers, Bram A., Rygg, Marite, Saag, Kenneth G., Salmon, Jane E., Salusky, Isidro B., Salvarani, Carlo, Sandell, Linda J., Sandhu, Vaneet K., Sandovici, Maria, Sand-Svartrud, Anne-Lene, Scanzello, Carla R., Schaible, Hans-Georg, Scher, Jose U., Schett, Georg, Schiffenbauer, Adam I., Schiller, Alan L., Schlesinger, Naomi, Schreiber, Benjamin E., Schwartz, Daniella M., Shaibani, Aziz, Sharma, Leena, Shmerling, Robert H., Siaton, Bernadette C., Siegel, Richard M., Sieghart, Daniela, Silverman, Stuart L., Simard, Julia F., Simmons, Barry P., Simms, Robert W., Singer, Nora G., Sirotich, Emily, Smith, Judith A., Smith, Stacy E., Smolen, Josef S., Solomon, Daniel H., Sparks, Jeffrey A., Stack, John, Stanley, David, Steen, Virginia D., Steere, Allen C., Stegeman, Coen A., Steiner, Günter, Steinert, Andre F., Stojan, George, Strand, Vibeke, Sufka, Paul, Sullivan, James K., Szulc, Pawel, Tang, Chen, Tang, Shiyu, Taylor, Peter C., Terkeltaub, Robert, Thomas, Afton R., Thorne, Jennifer E., Topping, Louise M., Toprover, Michael, Torralba, Karina, Touma, Zahi, Tremoulet, Adriana H., Trouw, Leendert, Tuan, Rocky S., Uçkay, Ilker, Umehara, Hisanori, van der Geest, Kornelis S.M., van der Heijde, Désirée, van Gaalen, Floris A., Van Mechelen, Margot, van Vollenhoven, Ronald F., Vandevelde, Claire Y.J., Varga, John, Vassilopoulos, Dimitrios, Veale, Douglas J., Verstappen, Gwenny M., Viatte, Sebastien, Vincent, Tonia L., Vital, Edward M., von Loga, Isabell S., Wahezi, Dawn M., Wallace, Daniel J., Wallace, Zachary S., Warburton, Gary, Watad, Abdulla, Watts, Richard A., Weinblatt, Michael E., Weir, Matthew R., Weisman, Michael H., Weiss, Pamela F., Branford White, Harriet, White, Kenneth E., Wilkinson, David J., Williams, David E., Williams, Richard, Wilson, Hannah, Winthrop, Kevin L., Witt, Claudia M., Witzmann, Gerhard, Wong, John B., Woolf, Anthony D., Paul Wordsworth, B., Xu, Huji, Yazdany, Jinoos, Young, David A., Young, Stephen P., Md Yusof, Md Yuzaiful, and Zhuang, Haoyang

Published
2023
Full Text
View/download PDF

47. Does biologic therapy impact the development of PsA among patients with psoriasis?

Author

Meer, Elana, Merola, Joseph F., Fitzsimmons, Robert, Jon Love, Thorvardur, Shiyu Wang, Shin, Daniel, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Scher, Jose U., Ritchlin, C. T., Gelfand, Joel M., Ogdie, Alexis, Love, Thorvardur Jon, Wang, Shiyu, Chen, Yong, Xie, Sharon, Choi, Hyon, and Zhang, Yuqing

Subjects
BIOTHERAPY, PSORIASIS treatment, PSORIATIC arthritis, RESEARCH, PHOTOTHERAPY, ORAL drug administration, RESEARCH methodology, RETROSPECTIVE studies, DISEASE incidence, EVALUATION research, COMPARATIVE studies, DERMATOLOGIC agents
Abstract

Objective: To examine the association of biologic therapy use for psoriasis with incident psoriatic arthritis (PsA) diagnosis.Methods: A retrospective cohort study was conducted in the OptumInsights Electronic Health Record Database between 2006 and 2017 among patients with psoriasis between the ages of 16 and 90 initiating a therapy for psoriasis (oral, biologic or phototherapy). The incidence of PsA was calculated within each therapy group. Multivariable Cox models were used to calculate the HR for biologic versus oral or phototherapy using biologics as a time-varying exposure and next in a propensity score-matched cohort.Results: Among 1 93 709 patients with psoriasis without PsA, 14 569 biologic and 20 321 cumulative oral therapy and phototherapy initiations were identified. Mean age was lower among biologic initiators compared with oral/phototherapy initiators (45.9 vs 49.8). The incidence of PsA regardless of therapy exposure was 9.75 per 1000 person-years compared with 77.26 among biologic users, 61.99 among oral therapy users, 26.11 among phototherapy users and 5.85 among those without a prescription for one of the target therapies. Using a multivariable adjustment approach with time-varying exposure, adjusted HR (95% CI) for biologic users was 4.48 (4.23 to 4.75) compared with oral or phototherapy users. After propensity score matching, the HR (95% CI) was 2.14 (2.00 to 2.28).Conclusions: In this retrospective cohort study, biologic use was associated with the development of PsA among patients with psoriasis. This may be related to confounding by indication and protopathic bias. Prospective studies are needed to address this important question. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.

Author

Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, Castillo R, Cornelius AR, Rackoff P, Solomon G, Adhikari S, Azar N, Rosenthal P, Izmirly P, Samuels J, Golden B, Reddy SM, Neurath MF, Abramson SB, Schett G, Mulligan MJ, and Scher JU

Abstract

Objective: To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment., Methods: Established patients at New York University Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunisation. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analysed for humoral response. Cellular immune response to SARS-CoV-2 was further analysed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany, were also analysed for humoral immune response., Results: Although healthy subjects (n=208) and patients with IMID on biologic treatments (mostly on tumour necrosis factor blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, patients with IMID on methotrexate do not demonstrate an increase in CD8+ T-cell activation after vaccination., Conclusions: In two independent cohorts of patients with IMID, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut-offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunisation efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines., Competing Interests: Competing interests: JUS declares that he has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, UCB and Abbvie and has received funding for investigator-initiated studies from Novartis, Sanofi and Janssen. GS has served as a consultant for Abbvie, BMS, Eli Lilly, Gilead, GSK Novartis, Janssen and Roche and has received funding for investigator-initiated studies from BMS, Eli Lilly, GSK, Novartis and UCB. MM declares grants from Eli Lilly, Pfizer and Sanofi and personal fees from Meissa Vaccines. PI has received consulting fees from GSK. RHH has received consulting from Janssen. SA reports grant support from Johnson and Johnson. GS declares consulting fees from AbbVie., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results